Degree of cognitive impairment does not signify early versus late mild cognitive impairment: confirmation based on Alzheimer's disease polygenic risk.
Alzheimer’s disease (AD)
Diagnostic criteria
Mild cognitive impairment (MCI)
Polygenic risk scores (PRS)
Journal
Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
06
03
2020
revised:
28
05
2020
accepted:
31
05
2020
pubmed:
6
7
2020
medline:
30
6
2021
entrez:
6
7
2020
Statut:
ppublish
Résumé
Degree of memory impairment is often used to infer early versus late amnestic mild cognitive impairment (aMCI). Previously, 318 Alzheimer's Disease Neuroimaging Initiative participants with aMCI-determined by a single memory test-were divided based on Rey Auditory Verbal Learning Task (AVLT) delayed recall: AVLT-impaired (n = 225) and AVLT-normal (n = 93). Equally consistent with differential progression or differential diagnosis, the AVLT-impaired group had more abnormal Alzheimer's disease (AD) biomarkers, more neurodegeneration over time, and was more likely to develop AD. In the present study, higher AD polygenic risk scores were associated with increased odds of being AVLT-impaired (odds ratio 1.8, p < 0.001). Thus, impairment severity does not necessarily reflect early versus late aMCI because disease progression cannot alter polygenic risk. Presumed early MCI is likely a heterogeneous category that includes excess false-positives. The additional cognitive test improved diagnostic precision by reducing false positives. Impairment severity may reflect differences in underlying disease risk but cannot be used to infer early versus late MCI based on cross-sectional data alone.
Identifiants
pubmed: 32623261
pii: S0197-4580(20)30184-6
doi: 10.1016/j.neurobiolaging.2020.05.015
pmc: PMC7483806
mid: NIHMS1603114
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-153Subventions
Organisme : NIA NIH HHS
ID : R01 AG022982
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG018386
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG018384
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG024904
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001444
Pays : United States
Organisme : CIHR
Pays : Canada
Organisme : NIA NIH HHS
ID : R01 AG022381
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG050595
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Science. 2018 Jun 22;360(6395):
pubmed: 29930110
Int J Epidemiol. 2014 Apr;43(2):600-10
pubmed: 24370560
Gigascience. 2019 Jul 1;8(7):
pubmed: 31307061
Ann Neurol. 2017 Aug;82(2):311-314
pubmed: 28727176
Neurology. 2010 Jan 19;74(3):201-9
pubmed: 20042704
Brain Imaging Behav. 2020 Jun;14(3):787-796
pubmed: 30511118
Am J Geriatr Psychiatry. 2009 May;17(5):368-75
pubmed: 19390294
Arch Neurol. 2010 Nov;67(11):1364-9
pubmed: 21060013
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Alzheimers Dement. 2010 May;6(3):239-46
pubmed: 20451872
Brain. 2015 Dec;138(Pt 12):3673-84
pubmed: 26490334
Nat Genet. 2013 Dec;45(12):1452-8
pubmed: 24162737
Alzheimers Dement. 2015 Apr;11(4):415-24
pubmed: 24857234
Neurobiol Aging. 2019 Dec;84:1-8
pubmed: 31479859
Mol Psychiatry. 2019 Mar;24(3):421-430
pubmed: 29487403
Alzheimers Dement (Amst). 2020 Apr 11;12(1):e12004
pubmed: 32284960
J Alzheimers Dis. 2014;42(1):275-89
pubmed: 24844687
J Alzheimers Dis. 2016 Mar 31;52(2):685-91
pubmed: 27031477
Alzheimers Dement. 2010 May;6(3):265-73
pubmed: 20451875